UK Study Leads to Better Understanding of Blood Pressure Regulation, Atherosclerosis

Photo from Getty Images.
Photo from Getty Images.

LEXINGTON, Ky. (Sept. 2, 2020) — A new University of Kentucky College of Medicine study provides insight into how a protein called angiotensinogen (AGT) contributes to blood pressure regulation and atherosclerosis.

AGT is a member of the renin-angiotensin system, a hormone system in the human body that regulates blood pressure and fluid balance. AGT produces angiotensin II, which regulates blood pressure and contributes to atherosclerosis, or the buildup of plaque in the arteries.

When forming angiotensin II, amino acids are “clipped off” of the AGT protein. The study, co-led by Saha Cardiovascular Research Center researchers Hong Lu and Alan Daugherty, found that replacing the amino acids in AGT did not affect blood pressure or atherosclerosis in mice.

The findings may mean that these amino acids in AGT that were thought of as critical regulators of blood pressure and atherosclerosis may not be as critical as initially thought. A better understanding of the peptide that causes blood pressure changes may provide insight into future drug development, Daugherty says.

“High blood pressure is an extremely common manifestation that is very difficult to treat, The more that is known about the structure of AGT and how it functions can potentially change the way high blood pressure is managed and lessen the chronic disease effects of increasing blood pressure and atherosclerosis,” said Daugherty.

The study used a unique mouse model that lacked AGT in the liver and used a state-of-the-art technique to change the amino acids of the protein in the liver. These tools enabled the team to study whether changes of amino acids in AGT influence blood pressure and atherosclerosis.

The research team is continuing to look at different sequences that are thought to have functional importance to learn more about how the body handles AGT to affect blood pressure. 

In addition to Lu and Daugherty, the research team includes Lisa A. Cassis from the Department of Pharmacology and Nutritional Sciences, as well as Saha Cardiovascular Research Center researchers Chia-Hua Wu, Congqing Wu, Deborah A. Howatt and Jessica J. Moorleghen.

The study was published in the September issue of Arteriosclerosis, Thrombosis, and Vascular Biology. This work was supported by funding from the National Heart, Lung and Blood Institute from the National Institutes of Health.


The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers."  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.